Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

2nd International Conference on Non-invasive Cardiac Imaging, Nuclear Cardiology & Echocardiography

Amsterdam, Netherlands

Marc Spaanderman

Marc Spaanderman

Maastricht University , Netherlands

Title: Risk group identification, prevention and early detection of Hypertensive Disorders of Pregnancy (HDP)

Biography

Biography: Marc Spaanderman

Abstract

Statement of the problem: Vascular complications may arise from pre-existing cardiovascular risk factors that lower the capability to withhold the increased hemodynamic mechanical and biochemical burden of gestation or from reduced physiological adaptive capability during the first half of gestation. Although the biological diversity in jeopardizing actions of associate risk factors implies tailored preventive measures, so far, most developed preventive strategies are rather generic than specific. Systematic risk analysis of those having encountered vascular complications throughout gestation may shed light on underlying dis-orders and with it tailored preventive strategies (Fig 1). Moreover, early-pregnancy maternal adaptive responses may additionally identify those at increased risk.

Methodology and theoretical orientation: Prior to pregnancy, short sys-tematic evaluation of associated risk factors consistent with the metabolic syndrome and larger evaluation in those with prior vascular complicated pregnancy or preexisting disease associated with gestational vascular disorders may detect those at increased risk. Circulatory follow-up throughout the first half of gestation could be helpful in detecting those failing to circulatory adjust properly, increasing their risk additionally.

Findings: Generic preventive measures, such as aspirin and calcium, should be discussed in those with anticipated increased risk. Precision medication should be offered to those with serious underlying disorders as SLE and antiphospholipid syndrome, kidney disease, prior thrombotic events, chronic hypertension or cardiac failure. In order to improve maternal outcome, antihypertensive drugs should be instituted at the level of mild to moderate hypertension throughout gestation.

Conclusion and significance: Vascular complications in pregnancy may arise from preexisting cardiovascular, cardio-metabolic, hemostatic or autoimmunological risk factors. Besides generic preventive actions, precision measures can be discussed and taken depending on personal underlying disorders.

Figure 1; underlying hemodynamic, metabolic and hemostatic risk factors in 1234 non-pregnant formerly preeclampic women. (Adapted and modi-fied from reference 1)

References:

  1. Scholten R et al. Co-occurrence of cardiovascular and prothrombotic risk factors in women with a history of preeclampsia. Obstet Gynecol. 2013 Jan;121(1):97-105.
  2. Roberge S et al. The role of aspirin dose on the prevention of pre-eclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2016: S0002-9378(16) 30783-9.
  3. Hofmeyr G et al. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014 Jun 24;(6):CD001059.
  4. Abalos E et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014 Feb6;(2): CD002252.
  5. Magee L et al. Less-tight versus tight control of hypertension in preg-nancy. N Engl J Med. 2015 Jan 29;372(5):407-17.